MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma

Jing Zhang; Lei Guo; Xiuyun Liu; Wenbin Li; Jianming Ying

doi:10.18632/oncotarget.14382

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma

Jing Zhang, Lei Guo, Xiuyun Liu, Wenbin Li and Jianming Ying _

PDF | HTML | How to cite

Oncotarget. 2017; 8:10264-10273. https://doi.org/10.18632/oncotarget.14382

Metrics: PDF 1751 views | HTML 2377 views | ?

Abstract

Jing Zhang1, Lei Guo1, Xiuyun Liu1, Wenbin Li1, Jianming Ying1

1Department of Pathology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China

Correspondence to:

Jianming Ying, email: [email protected]

Keywords: gastric cancer, MET overexpression, MET gene amplification, biomarker, immunohistochemistry

Received: October 21, 2016 Accepted: December 13, 2016 Published: December 30, 2016

ABSTRACT

This study was conducted to investigate the expression of MET in Chinese gastric adenocarcinoma cohort, the correlation between MET overexpression and clinical pathological features, HER2 expression and MET gene amplification. A total of 816 gastric adenocarcinoma patients were included and MET and HER2 immunohistochemical (IHC) staining were performed. IHC and dual-color silver in situ hybridization analysis were performed in the tissue microarrays, constructed from the 240 patients who were randomly selected. MET overexpression (IHC 3+) was observed in 6.0% (49/816) of the cohort. MET overexpression rate was higher in patients with poor prognostic factors, such as clinical stages III/IV (p =0.012) and pathologic stages T3/T4 (p =0.027). The HER2 overexpression (IHC 3+) rate was 8.8% (72/816) and MET overexpression rate was higher in HER2 positive patients (9.7%, 7/72). A high concordance rate (94.6%) between MET overexpression and gene amplification was demonstrated. Therefore, MET overexpression could serve as a prognostic biomarker and a potential therapeutic target for gastric cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14382

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma

Abstract